Frederick C. Eilber

634 total citations
21 papers, 484 citations indexed

About

Frederick C. Eilber is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Frederick C. Eilber has authored 21 papers receiving a total of 484 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Frederick C. Eilber's work include Sarcoma Diagnosis and Treatment (19 papers), Vascular Tumors and Angiosarcomas (7 papers) and Gastrointestinal Tumor Research and Treatment (6 papers). Frederick C. Eilber is often cited by papers focused on Sarcoma Diagnosis and Treatment (19 papers), Vascular Tumors and Angiosarcomas (7 papers) and Gastrointestinal Tumor Research and Treatment (6 papers). Frederick C. Eilber collaborates with scholars based in United States, Japan and Italy. Frederick C. Eilber's co-authors include Charles Forscher, Jeffrey J. Eċkardt, Susan Lowenbraun, Gerald Rosen, Yao Fu, Michael T. Selch, Michael W. Kattan, Steve P. Lee, Yao‐Shi Fu and Sant P. Chawla and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Frederick C. Eilber

18 papers receiving 476 citations

Peers

Countries citing papers authored by Frederick C. Eilber

Since Specialization

Citations

This map shows the geographic impact of Frederick C. Eilber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frederick C. Eilber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frederick C. Eilber more than expected).

Fields of papers citing papers by Frederick C. Eilber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frederick C. Eilber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frederick C. Eilber. The network helps show where Frederick C. Eilber may publish in the future.

Co-authorship network of co-authors of Frederick C. Eilber

This figure shows the co-authorship network connecting the top 25 collaborators of Frederick C. Eilber. A scholar is included among the top collaborators of Frederick C. Eilber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frederick C. Eilber. Frederick C. Eilber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dedicated review of sarcoma pathology is necessary for corroborative diagnosis in nearly one half of referred patients 2025 ·Surgery ·Mark A. Eckardt, (unknown), Amy R. Copeland, Tyler R. McCaw, (unknown), Serena Lofftus, (unknown), (unknown), Arun S. Singh, Bartosz Chmielowski, Noah Federman, Brian E. Kadera, (unknown), Nicholas M. Bernthal, Frederick C. Eilber, Sarah Dry, Scott D. Nelson, Fritz C. Eilber, Joseph G. Crompton	0
2	A Phase II Trial of 5-Day Neoadjuvant Radiation Therapy for Patients with High-Risk Primary Soft Tissue Sarcoma: Long-Term Follow-Up and Outcomes 2024 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), (unknown), Ricky R. Savjani, Nicholas Jackson, Jie Deng, (unknown), (unknown), Brian E. Kadera, Joseph G. Crompton, Lucas M. Wessel, Bartosz Chmielowski, Arun S. Singh, Scott D. Nelson, Sarah Dry, Joanne B. Weidhaas, Michael L. Steinberg, Nicholas M. Bernthal, Frederick C. Eilber, Anusha Kalbasi, Vishruth K. Reddy	1
3	The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model 2019 ·Biomedicine & Pharmacotherapy ·Takashi Higuchi, Kei Kawaguchi, Kentaro Miyake, Hiromichi Oshiro, Zhiying Zhang, Sahar Razmjooei, Sintawat Wangsiricharoen, Kentaro Igarashi, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Scott D. Nelson, Sarah Dry, Yunfeng Li, Sant P. Chawla, Frederick C. Eilber, Shree Ram Singh, Hiroyuki Tsuchiya, Robert M. Hoffman	11
4	A randomized phase II study of nivolumab monotherapy versus nivolumab combined with ipilimumab in advanced gastrointestinal stromal tumor (GIST). 2019 ·Journal of Clinical Oncology ·Arun S. Singh, Bartosz Chmielowski, J. Randolph Hecht, Lee S. Rosen, Warren Chow, Xiaoyan Wang, (unknown), Carlos Adame, (unknown), (unknown), Michael Douek, (unknown), (unknown), Frederick C. Eilber, John A. Glaspy	18
5	Pathologic discordance in sarcomas: Prospective comparison of external and sarcoma center pathologic diagnosis. 2019 ·Journal of Clinical Oncology ·Mark A. Eckardt, (unknown), Arun S. Singh, Bartosz Chmielowski, Noah Federman, Anusha Kalbasi, Nicholas M. Bernthal, Susan V. Bukata, Francis J. Hornicek, Jane Yanagawa, Benjamin D. Levine, Kambiz Motamedi, Leanne L. Seeger, Jeffrey J. Eċkardt, Frederick R. Eilber, Sarah Dry, Scott D. Nelson, Frederick C. Eilber	3
6	Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model 2018 ·Anticancer Research ·Takashi Higuchi, Kei Kawaguchi, Kentaro Miyake, Qinghong Han, Yuying Tan, Hiromichi Oshiro, Norihiko Sugisawa, Zhiying Zhang, Sahar Razmjooei, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Kentaro Igarashi, Sant P. Chawla, Arun S. Singh, Frederick C. Eilber, Shree Ram Singh, Hiroyuki Tsuchiya, Robert M. Hoffman	61
7	A randomized phase 2 study of nivolumab monotherapy versus nivolumab combined with ipilimumab in patients with metastatic or unresectable gastrointestinal stromal tumor (GIST). 2018 ·Journal of Clinical Oncology ·Arun S. Singh, Bartosz Chmielowski, J. Randolph Hecht, Lee S. Rosen, Xiaoyan Wang, (unknown), Carlos Adame, Paulina Linares, (unknown), (unknown), Frederick C. Eilber	9
8	Administration of aldoxorubicin and 14 days continuous infusion of ifosfamide/mesna in metastatic or locally advanced sarcomas. 2017 ·Journal of Clinical Oncology ·Frederick C. Eilber, Kamalesh K. Sankhala, Sant P. Chawla, (unknown), Erlinda M. Gordon, (unknown), Katherine Kim, (unknown), Nancy Wu, Scott Wieland, Daniel Levitt	5
9	Radiation Treatment Planning for Soft Tissue Sarcomas 2015 ·Frontiers of radiation therapy and oncology ·Robert G. Parker, Michael T. Selch, Frederick C. Eilber, (unknown)	0
10	Correlation of PTEN loss and PI3K/AKT/mTOR pathway upregulation with malignant peripheral nerve sheath tumor (MPNST) development and outcome. 2013 ·Journal of Clinical Oncology ·Elizabeth Shurell, (unknown), (unknown), Linh M. Tran, Jonathan Nakashima, (unknown), (unknown), Nicholas M. Bernthal, William D. Tap, Jeffrey J. Eċkardt, Frederick R. Eilber, Sarah Dry, Hong Wu, Frederick C. Eilber	1
11	Long-term follow-up (>20 years) for one of the original randomized prospective trials evaluating adjuvant chemotherapy in patients with high-grade operable osteosarcoma 2009 ·Journal of Clinical Oncology ·William D. Tap, Frederick R. Eilber, Gerald Rosen, J J Eckardt, Anna L. Schwartz, Noah Federman, Frederick C. Eilber	0
12	Sarcoma Nomogram: Validation and a Model to Evaluate Impact of Therapy 2007 ·Journal of the American College of Surgeons ·Frederick C. Eilber, Michael W. Kattan	18
13	Change in quantitative FDG-PET was significantly more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high grade soft tissue sarcomas 2007 ·Journal of Clinical Oncology ·Vladimir Evilevitch, Wolfgang Weber, William D. Tap, Kira Chow, Martin Allen-Auerbach, (unknown), Frederick R. Eilber, (unknown), (unknown), Frederick C. Eilber	1
14	A phase II study of AP23573 (an mTOR inhibitor) in patients (pts) with advanced sarcomas 2005 ·Journal of Clinical Oncology ·Sant P. Chawla, Kamalesh K. Sankhala, (unknown), Lawrence R. Menendez, Frederick C. Eilber, (unknown), (unknown), Garima Rana, Camille L. Bedrosian, G. D. Demetri	16
15	Impact of ifosfamide-based chemotherapy on survival in patients with primary extremity synovial sarcoma 2004 ·Journal of Clinical Oncology ·Frederick C. Eilber, Frederick R. Eilber, J J Eckardt, (unknown), Charles Forscher, Robert G. Maki, Stephen R. Grobmyer, Matt Brennan, S. J. Singer	2
16	Impact of ifosfamide-based chemotherapy on survival in patients with primary extremity synovial sarcoma 2004 ·Journal of Clinical Oncology ·Frederick C. Eilber, Frederick R. Eilber, (unknown), (unknown), Charles Forscher, Robert G. Maki, Stephen R. Grobmyer, Murray F. Brennan, Steven R. Singer	8
17	Treatment Results of Unresected or Partially Resected Desmoid Tumors 1998 ·American Journal of Clinical Oncology ·Barry W. Goy, Steve P. Lee, Yao‐Shi Fu, Michael T. Selch, Frederick C. Eilber	30
18	Synovial sarcoma. Uniform response of metastases to high dose ifosfamide 1994 ·Cancer ·Gerald Rosen, Charles Forscher, Susan Lowenbraun, Frederick C. Eilber, Jeffrey J. Eċkardt, (unknown), Yao Fu	203
19	Synovial sarcoma. A study of intensive chemotherapy in 14 patients with localized disease 1993 ·Cancer ·(unknown), Gerald Rosen, Frederick C. Eilber, Jeffrey J. Eċkardt, Susan Lowenbraun, (unknown), Charles Forscher, Michael T. Selch	93
20	A Study of Intensive Chemotherapy in 14 Patients with Localized Disease 1993 ·(unknown), Gerald Rosen, Frederick C. Eilber, (unknown), Susan Lowenbraun, (unknown), Charles Forscher, Michael T. Selch	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact